CD30+ neoplasms of the skin

Current Hematologic Malignancy Reports

Volumn 6, Issue 4, 2011, Pages 245-250

  Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

ALCL; Anaplastic large T cell lymphoma; Anaplastic lymphoma kinase; CD30; Cutaneous T cell lymphoma; Hodgkin's lymphoma; Interferon regulatory factor 4; Ki 1; Large cell transformation; Lymphoma; Lymphomatoid papulosis; LyP; Mycosis fungoides; Tumor necrosis factor member 8

Indexed keywords

BEXAROTENE; CD30 ANTIGEN; DENILEUKIN DIFTITOX; EPITHELIAL MEMBRANE ANTIGEN; PSEUDOMONIC ACID; TUMOR NECROSIS FACTOR;

APOPTOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CELL DIFFERENTIATION; CUTANEOUS T CELL LYMPHOMA; EOSINOPHIL; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOID PAPULOSIS; MONOCYTE; MYCOSIS FUNGOIDES; NEUTROPHIL; NONHUMAN; OVERALL SURVIVAL; PATHOGENESIS; PHOTOTHERAPY; PROTEIN EXPRESSION; PUVA; REVIEW; SEZARY SYNDROME; SIGNAL TRANSDUCTION;

ANTIGENS, CD30; BIOLOGICAL MARKERS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MYCOSIS FUNGOIDES; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 81355138634     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0096-8     Document Type: Review

References (31)

1. R Willemze ES Jaffe G Burg L Cerroni E Berti SH Swerdlow 2005 WHO-EORTC classification for cutaneous lymphomas Blood 105 3768 3785 15692063 10.1182/blood-2004-09-3502 1:CAS:528:DC%2BD2MXktlSrs74%3D (Pubitemid 40656118)
2. R Schwarting J Gerdes H Dürkop B Falin S Pileri H Stein 1989 BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope Blood 74 5 1678 89 2477085 1:CAS:528:DyaL1MXlvFalurY%3D (Pubitemid 19251546)
3. SK Lau P Thomas LM Weiss 2010 Immunohistochemical evaluation of CON6D/B5: a new CD30 monoclonal antibody Appl Immunohistochem Mol Morphol 18 3 273 7 20090517 10.1097/PAI.0b013e3181c81d31 1:CAS:528:DC%2BC3cXltFCkurc%3D
4. O Josimovic-Alasevic H Durkop R Schwarting E Backé H Stein T Diamantstein 1989 Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay Eur J Immunol 19 1 157 62 2537734 10.1002/eji.1830190125 1:CAS:528:DyaL1MXhslWgtr4%3D (Pubitemid 19069302)
5. K Miyake T Yoshino AB Sarker N Teramoto T Akagi 1994 CD30 antigen in non-Hodgkin's lymphoma Pathol Int 44 6 428 34 8055109 10.1111/j.1440-1827.1994. tb01706.x 1:STN:280:DyaK2czjt1ejtA%3D%3D (Pubitemid 24193676)
6. H Muta LH Boise L Fang ER Podack 2000 CD30 signals integrate expression of cytotoxic effector molecules, lymphocyte trafficking signals, and signals for proliferation and apoptosis J Immunol 165 5105 11 11046041 1:CAS:528: DC%2BD3cXnvVOnsbk%3D
7. Umeda K, Sun X, Guo Y, Yamada H, Shibata K, Yoshikai Y. Innate memory phenotype CD4(+) T cells play a role in early protection against infection with Listeria monocytogenes in a CD30L-dependent manner. Microbiol Immunol 2011 Jun 24 (Epub ahead of print).
8. M Saraiva P Smith PG Fallon A Alcami 2002 Inhibition of type I cytokine-mediated inflammation by a Solubel CD30 homologue encoded by ectromelia (mousepox) virus J Exp Med 196 6 829 39 12235215 10.1084/jem.20020319 1:CAS:528:DC%2BD38Xnt1yhtLo%3D
9. G Del Prete M De Carli F Almerigogna CK Daniel MM D'Elios G Zancuoghi F Vinante G Pizzolo S Romagnani 1995 Preferential expression of CD30 by human CD4+ T cells producing Th2-type cytokines FASEB J 9 81 86 7821763
10. WL Macaulay 1968 Lymphomatoid papulosis. A continuing self-healing eruption, clinically benign - histologically malignant Arch Dermatol 97 1 23 30 5634442 10.1001/archderm.97.1.23 1:STN:280:DyaF1c%2Fos1aktQ%3D%3D
11. A Saggini A Gulia Z Argenyi R Fink-Puches A Lissia M Magaña L Requena I Simonitsch L Cerron 2010 A variant of lymphomatoid papulosis simulating primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma. Description of 9 cases Am J Surg Pathol 34 8 1168 75 20661014 10.1097/PAS.0b013e3181e75356
12. • Morimura S, Sugaya M, Tamaki Z, Takekoshi T, Sato S. lymphomatoid papulosis showing γδ T-cell phenotype. Acta Derm Venereol 2011 Jun 1 (Epub ahead of print). This reference and reference [11] introduces the concept of LyP having CD8+ or γδ T-cell phenotypes and the need to separate these types from more aggressive tumors.
13. ME Kadin E Levi W Kempf 2001 Progression of lymphomatoid papulosis to systemic lymphoma is associated with escape from growth inhibition by transforming growth factor-beta and CD30 ligand Ann N Y Acad Sci 941 59 68 11594583 10.1111/j.1749-6632.2001.tb03711.x 1:CAS:528:DC%2BD3MXnslKgu7s%3D (Pubitemid 32928334)
14. O Zoi-Toli MH Vermeer E De Vries P Van Beek CJ Meijer R Willemze 2000 Expression of Fas and Fas-ligand in primary cutaneous T-cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL Br J Dermatol 143 2 313 319 10951138 10.1046/j.1365-2133.2000.03656.x 1:CAS:528:DC%2BD3cXmsF2ntrw%3D (Pubitemid 30650398)
15. MW Bekkenk FA Geelen PC van Voorst Vader F Heule ML Geerts WA van Vloten CJ Meijer R Willemze 2000 Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment Blood 95 12 3653 61 10845893 1:CAS:528:DC%2BD3cXktFChsL4%3D (Pubitemid 30412833)
16. J Kunishige H McDonald G Alvarez M Johnson V Prieto M Duvic 2009 Lymphomatoid papulosis and associated lymphomas: a retrospective case series of 84 patients Clin Exp Dermatol 34 5 576 81 19196298 10.1111/j.1365-2230.2008. 03024.x 1:STN:280:DC%2BD1MvgsVeitQ%3D%3D This is the most recent large case series of LyP patients, showing a secondary malignancy rate of 40% and multivariable risk factor analysis
17. H Stein HD Foss H Durkop T Marafioti G Delsol K Pulford, et al. 2000 CD30+ anaplastic large T-cell lymphoma: a review of its histopathologic, genetic, and clinical features Blood 96 3681 95 11090048 1:CAS:528: DC%2BD3cXosVGnt7g%3D
18. DA Wada ME Law ED Hsi L Ma MS Lim A Souza NI Comfere RH Weenig WR Macon LA Erickson N Ozsan SM Ansell A Dogan AL Feldman 2011 Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies Mod Pathol 24 4 596 605 21169992 10.1038/modpathol.2010.225 1:CAS:528:DC%2BC3MXktFGjtLw%3D
19. ME Kadin C Carpenter 2003 Systemic and primary cutaneous anaplastic large cell lymphomas Semin Hematol 40 3 244 56 12876673 10.1016/S0037-1963(03)00138-0 1:CAS:528:DC%2BD3sXmsV2ls7s%3D (Pubitemid 36842602)
20. AH Sarris R Luthra V Papadimitracopoulou M Waasdorp MA Dimopoulos JA McBride F Cabanillas M Duvic A Deisseroth SW Morris WC Pugh 1996 Amplification of genomic DNA demonstrates the presence of the t(2;5) (p23;q35) in anaplastic large cell lymphoma, but not in other non-Hodgkin's lymphomas, Hodgkin's disease, or lymphomatoid papulosis Blood 88 5 1771 9 8781434 1:CAS:528:DyaK28Xlt1Kkurc%3D (Pubitemid 26307074)
21. MM Tomaszewski JC Moad GP Lupton 1999 Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood J Am Acad Dermatol 40 5 Pt 2 857 61 10321635 10.1053/jd.1999.v40.a95960 1:STN:280:DyaK1M3ltlGmsA%3D%3D (Pubitemid 29230344)
22. AK Wong J Lopategui S Clancy D Kulber S Bose 2008 Anaplastic large cell lymphoma associated with a breast implant capsule: a case report and review of the literature Am J Surg Pathol 32 8 1265 8 18594466 10.1097/PAS. 0b013e318162bcc1
23. L Lipworth RE Tarone JK McLaughlin 2009 Breast implants and lymphoma risk: a review of the epidemiologic evidence through 2008 Plast Reconstr Surg 123 3 790 3 19319041 10.1097/PRS.0b013e318199edeb 1:CAS:528:DC%2BD1MXjt1yrsLg%3D
24. L Cerroni C Beham-Schmid H Kerl 1995 Cutaneous Hodgkin's disease: an immunohistochemical analysis J Cutan Pathol 22 3 229 35 7593816 10.1111/j.1600-0560.1995.tb00743.x 1:STN:280:DyaK28%2Fot1alsw%3D%3D
25. R Talpur DM Jones AJ Alencar N Apisarnthanarax KL Herne Y Yang M Duvic 2006 CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma J Invest Dermatol 126 3 575 83 16410787 10.1038/sj.jid.5700122 1:CAS:528:DC%2BD28XhsVSrsbo%3D (Pubitemid 43255644)
26. AG Perna DM Jones M Duvic 2004 Lymphomatoid papulosis from childhood with anaplastic large cell lymphoma of the small bowel Clin Lymphoma 5 3 190 3 15636695 10.3816/CLM.2004.n.025 (Pubitemid 40227711)
27. R Willemze RC Beljaards 1993 Spectrum of primary cutaneous CD30 (Ki-1)-positive lymphoproliferative disorders: a proposal for classification and guidelines for management and treatment J Am Acad Dermatol 28 973 80 8388410 10.1016/0190-9622(93)70140-O 1:STN:280:DyaK3s3ms12nsg%3D%3D (Pubitemid 23160651)
28. JM Shehan AN Kalaaji SN Markovic I Ahmed 2004 Management of multifocal primary cutaneous CD30+ anaplastic large cell lymphoma J Am Acad Dermatol 51 103 10 15243534 10.1016/j.jaad.2003.12.028 (Pubitemid 38898663)
29. M Duvic SA Reddy L Pinter-Brown NJ Korman J Zic DA Kennedy J Lorenz EL Sievers YH Kim 2009 A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders Clin Cancer Res 15 19 6217 24 19789316 10.1158/1078-0432.CCR-09-0162 1:CAS:528:DC%2BD1MXhtF2lurvJ
30. A Younes NL Bartlett JP Leonard DA Kennedy CM Lynch EL Sievers A Forero-Torres 2010 Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas N Engl J Med 363 19) 1812 21 21047225 10.1056/NEJMoa1002965 1:CAS:528:DC%2BC3cXhtl2gsbbE This article, of outstanding importance, shows the efficacy of SGN-35, a novel conjugated antibody that has high response rates in CD30+ tumors
31. S Ingen-Housz-Oro H Bachelez O Verola C Lebbe JP Marolleau C Hennequin L Dubertret P Morel C Gisselbrecht P Brice 2004 High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma Bone Marrow Transplant 33 6 629 34 14755323 10.1038/sj.bmt.1704411 1:CAS:528:DC%2BD2cXhvVygtrs%3D (Pubitemid 38455925)